Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders.
Following the molecular cloning in the early 1990s of the metabotropic glutamate receptors (mGlu1-8), research that focused on the physiology, pharmacology and function of these receptors revealed their potential role in CNS disorders. Numerous psychiatric and neurological dis-orders are indeed linked to changes in excitatory processes, in which glutamate plays a key role. In contrast to ligand-gated ion channels [N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA) and kainate], which are responsible for fast excitatory transmission, mGlu receptors have a more modulatory role, by contributing to fine-tuning of synaptic efficacy, and control of the accuracy and sharpness of the transmission. Given the fact that the mGlu receptors are G-protein coupled, they obviously constitute new 'drugable' targets for the treatment of various CNS disorders. Due to the recent emergence of subtype-specific ligands for Group I and II mGlu receptors, this review will concentrate on the molecular characteristics, brain localization, pharmacology and physiological role of these receptors, in order to provide further insights into their therapeutic potential.
Spooren
W
W
F. Hoffmann-La Roche, Pharma Research Basel Dsicovery--Neuroscience, Basel, Switzerland. will.spooren@roche.com
Ballard
T
T
Gasparini
F
F
Amalric
M
M
Mutel
V
V
Schreiber
R
R
D000818:Animals; D001921:Brain / Q000378:metabolism*; D001927:Brain Diseases / Q000188:drug therapy / Q000378:metabolism*; D015640:Ion Channel Gating; D008024:Ligands; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*
D008024:Ligands; D018094:Receptors, Metabotropic Glutamate